LSP portfolio company Lumeon raises $ 30 million



Amsterdam, 12 August 2020. Lumeon, the leader in care pathway orchestration, successfully raised USD 30 million in a series D financing. The investment will be used to support U.S. growth, expand its care delivery platform solutions and enable deeper healthcare provider partnerships. LSP participated in the investment with its LSP HEF2 fund.

 

Lumeon's CPM platform uses real-time data to dynamically guide patients and care teams along their care journeys. By automating, orchestrating and virtualizing care delivery across care settings, Lumeon's solutions allow health systems to operate with predictability and efficiency, delivering optimal care to each patient while substantially lowering costs for healthcare providers.

 

"While the markets for data analytics, clinical decision support and patient engagement are well established, what is missing today is the ability to effectively connect them to solve the problem of personalizing care delivery in a scalable way,” said Lumeon Founder and CEO Robbie Hughes. “The ‘last mile’ that turns the insight into action is the hardest part for health systems, and is the core of the Lumeon proposition.”

 

Hughes continued, “This investment will allow us to continue on our rapid growth path, as we help healthcare systems develop and scale new models of delivery.”

 

"As the technology-driven transformation of healthcare is accelerated by COVID-19, Lumeon’s ability to optimize the care of every patient based on individual risk, cost, engagement and social determinants is crucial for their customers to operate effectively,” said Dr. Ashish Patel, representing new investor Optum Ventures on the board. “We believe Lumeon is uniquely positioned to help health systems unlock new opportunities in sustainable, profitable care delivery.”

 

Lumeon’s CPM platform integrates with all electronic health record (EHR) systems in addition to incorporating required clinical and administrative data from point solutions and devices, addressing the fragmented nature of healthcare technology and the challenge of interoperability. By extending beyond the confines of a healthcare provider’s EHR, Lumeon’s configurable solutions maximize current investments as organizations evolve their care delivery models.

 

"Lumeon’s flexible CPM platform offers an unparalleled solution to the care pathway challenges many health systems face,” said Alexander Schmitz, representing new investor Endeavour Vision on the board. “By coordinating processes across the continuum – from basic administrative tasks through to highly complex clinical optimization protocols – Lumeon is helping to define a new future for patient care.”

 

About Lumeon
Lumeon helps health systems take control of their care delivery processes by orchestrating and automating care journeys to operate with predictability and efficiency.
 
Its industry-leading solutions act as the ‘auto-pilot’ for healthcare delivery, navigating the patient care journey while coordinating care teams, communication, tasks, and decisions to increase revenue, optimize resource utilization, and deliver superior outcomes at less cost.
 
Lumeon’s solutions are enabled by their cloud-based care pathway management (CPM) platform. Capitalizing on the patient’s electronic health record (EHR), health systems can start simply with immediate benefits and evolve to orchestrate their entire care process.
 
More than 70 progressive health systems across 12 countries have deployed Lumeon’s multi-award-winning platform. lumeon.com
 
 
About LSP
LSP is one of the largest European investment firms providing financing for life sciences and health care companies. LSP’s management has raised over €2 billion ($2.3 billion) and developed more than 120 companies since it started to invest in 1988. From its offices in Amsterdam, Munich and Boston, LSP manages three distinct investment activities: LSP 6 invests in private early- to late-stage drug development and medical technology companies; LSP HEF 2 focuses on private late-stage medical technology companies with a health and economic benefit; and LSP Public targets public healthcare companies. Among LSP’s signature deals are argenx, Crucell, KuDOS, Movetis, Neuravi, Okairos, Prosensa, Qiagen and Zealand Pharma. In addition, LSP is an active contributor to the life sciences industry through roles as founder and board member of the Oncode Institute, initiator of the Dutch Venture Initiative (DVI), as well as board member of European venture capital associations, technology transfer institutes and government bodies. For more information: lspvc.com.
 
 
For further information, contact:
Rudy Dekeyser, Partner LSP
+31 20 664 55 00
 
 
« back to overview

go to archive back to news overview
Follow us

LSP portfolio company Lumeon raises $ 30 million



Amsterdam, 12 August 2020. Lumeon, the leader in care pathway orchestration, successfully raised USD 30 million in a series D financing. The investment will be used to support U.S. growth, expand its care delivery platform solutions and enable deeper healthcare provider partnerships. LSP participated in the investment with its LSP HEF2 fund.

 

Lumeon's CPM platform uses real-time data to dynamically guide patients and care teams along their care journeys. By automating, orchestrating and virtualizing care delivery across care settings, Lumeon's solutions allow health systems to operate with predictability and efficiency, delivering optimal care to each patient while substantially lowering costs for healthcare providers.

 

"While the markets for data analytics, clinical decision support and patient engagement are well established, what is missing today is the ability to effectively connect them to solve the problem of personalizing care delivery in a scalable way,” said Lumeon Founder and CEO Robbie Hughes. “The ‘last mile’ that turns the insight into action is the hardest part for health systems, and is the core of the Lumeon proposition.”

 

Hughes continued, “This investment will allow us to continue on our rapid growth path, as we help healthcare systems develop and scale new models of delivery.”

 

"As the technology-driven transformation of healthcare is accelerated by COVID-19, Lumeon’s ability to optimize the care of every patient based on individual risk, cost, engagement and social determinants is crucial for their customers to operate effectively,” said Dr. Ashish Patel, representing new investor Optum Ventures on the board. “We believe Lumeon is uniquely positioned to help health systems unlock new opportunities in sustainable, profitable care delivery.”

 

Lumeon’s CPM platform integrates with all electronic health record (EHR) systems in addition to incorporating required clinical and administrative data from point solutions and devices, addressing the fragmented nature of healthcare technology and the challenge of interoperability. By extending beyond the confines of a healthcare provider’s EHR, Lumeon’s configurable solutions maximize current investments as organizations evolve their care delivery models.

 

"Lumeon’s flexible CPM platform offers an unparalleled solution to the care pathway challenges many health systems face,” said Alexander Schmitz, representing new investor Endeavour Vision on the board. “By coordinating processes across the continuum – from basic administrative tasks through to highly complex clinical optimization protocols – Lumeon is helping to define a new future for patient care.”

 

About Lumeon
Lumeon helps health systems take control of their care delivery processes by orchestrating and automating care journeys to operate with predictability and efficiency.
 
Its industry-leading solutions act as the ‘auto-pilot’ for healthcare delivery, navigating the patient care journey while coordinating care teams, communication, tasks, and decisions to increase revenue, optimize resource utilization, and deliver superior outcomes at less cost.
 
Lumeon’s solutions are enabled by their cloud-based care pathway management (CPM) platform. Capitalizing on the patient’s electronic health record (EHR), health systems can start simply with immediate benefits and evolve to orchestrate their entire care process.
 
More than 70 progressive health systems across 12 countries have deployed Lumeon’s multi-award-winning platform. lumeon.com
 
 
About LSP
LSP is one of the largest European investment firms providing financing for life sciences and health care companies. LSP’s management has raised over €2 billion ($2.3 billion) and developed more than 120 companies since it started to invest in 1988. From its offices in Amsterdam, Munich and Boston, LSP manages three distinct investment activities: LSP 6 invests in private early- to late-stage drug development and medical technology companies; LSP HEF 2 focuses on private late-stage medical technology companies with a health and economic benefit; and LSP Public targets public healthcare companies. Among LSP’s signature deals are argenx, Crucell, KuDOS, Movetis, Neuravi, Okairos, Prosensa, Qiagen and Zealand Pharma. In addition, LSP is an active contributor to the life sciences industry through roles as founder and board member of the Oncode Institute, initiator of the Dutch Venture Initiative (DVI), as well as board member of European venture capital associations, technology transfer institutes and government bodies. For more information: lspvc.com.
 
 
For further information, contact:
Rudy Dekeyser, Partner LSP
+31 20 664 55 00
 
 
« back to overview

go to archive back to newsoverview